(MENAFN- GlobeNewsWire - Nasdaq) First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda ® (pembrolizumab) alone (10.8 months) and Keytruda ® + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback